Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Trellus Health's gross profit for the
six
months ended in Jun. 2025 was £0.22 Mil. Trellus Health's gross profit for the trailing twelve months (TTM) ended in Jun. 2025 was £0.27 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Trellus Health's gross profit for the
six
months ended in Jun. 2025 was £0.22 Mil. Trellus Health's Revenue for the
six
months ended in Jun. 2025 was £0.22 Mil. Therefore, Trellus Health's Gross Margin % for the quarter that ended in Jun. 2025 was N/A%.
Trellus Health had a gross margin of N/A% for the quarter that ended in Jun. 2025 => No sustainable competitive advantage
Trellus Health (LSE:TRLS) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Trellus Health had a gross margin of N/A% for the quarter that ended in Jun. 2025 => No sustainable competitive advantage
Trellus Health Gross Profit Related Terms
Trellus Health Gross Profit Historical Data
* Premium members only.
The historical data trend for Trellus Health's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:TRLS vs VEEV, BTSG, TEM: Gross Profit Comparison
For the Health Information Services subindustry, Trellus Health's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Trellus Health Gross Profit vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Trellus Health's Gross Profit distribution charts can be found below:
* The bar in red indicates where Trellus Health's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Jun. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.27 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
(Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Trellus Health (LSE:TRLS) has a Gross Profit of £0.27 Mil as of Jun. 2025. Gross Profit equals net sales less total cost of goods sold. View historical data on Trellus Health and its competitors.
Is Trellus Health's Gross Profit too high?
Trellus Health's current Gross Profit is £0.27 Mil.
How does Trellus Health's Gross Profit compare to VEEV and BTSG?
Trellus Health's Gross Profit of £0.27 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Healthcare Providers & Services company?
A good Gross Profit depends on the Healthcare Providers & Services industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on Trellus Health and its competitors. Trellus Health's current Gross Profit is £0.27 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Trellus Health stock overvalued right now?
Trellus Health (LSE:TRLS) has a current Gross Profit of £0.27 Mil. The current Gross Profit is £0.27 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For Trellus Health (LSE:TRLS), the current Gross Profit is £0.27 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Trellus Health PLC is commercializing the provision of digital chronic condition management solutions for employers and health plans that utilize the scientifically validated GRITT resilience-based methodology and a proprietary HIPAA-compliant technology platform called TrellusElevate to coordinate and deliver personalized care. The company is initially focused on Inflammatory Bowel Diseases, which include the chronic incurable conditions of Crohn's Disease and ulcerative colitis but considers its approach to have potential utility and demand across many chronic conditions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:TRLS has been successfully added to your 
